Maze Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $115.0Mattributed |
|---|---|
| Latest round | series-d+, $115.0M, 2024-12-01attributed |
| Founded | unknown |
| Headquarters | South San Francisco CA |
| Industry | biotech|therapeutics|metabolic |
| Stage | series-b+ |
| Website | mazetherapeutics.com |
Maze Therapeutics develops small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, including obesity. It serves patients with chronic kidney disease, led by MZE829 for APOL1 kidney disease and MZE782. Its Compass platform links genetic variants to disease pathways so therapies match genetically defined patient groups.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-12-01 | series-d+ | $115.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $115.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $115.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | mazetherapeutics.com, read 2026-05-07 |
| Description | self-reported | mazetherapeutics.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.